Portugal Dermatology Drugs Market Analysis Report 2022 to 2030

Portugal Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Portugal Dermatology drugs market will reach a value of $xx Mn from $51 Mn in 2022, growing at a CAGR of xx% during 2022-30. The market is primarily dominated by local players such as Roche Portugal, Eurofarma, and Bial. The market is driven by teledermatology consultations, the prevalence of dermatological diseases, and awareness about dermatological health. The dermatology drug market in Portugal is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10PTPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Portugal AUTHOR: Dr. Vishwa Modhia

Buy Now

Portugal Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Portugal Dermatology drugs market will reach a value of $xx Mn from $51 Mn in 2022, growing at a CAGR of xx% during 2022-30.

Skin conditions are treated with a variety of medications in dermatology in Portugal. Some of the medicines that are frequently used include topical corticosteroids, antibiotics, retinoids, calcineurin inhibitors, and immunosuppressants. The number of deaths from dermatological diseases in Portugal reached 202, or 0.22% of all deaths, according to the most recent WHO data published in 2020. The Portuguese government spent $2,317 per person on healthcare in 2019 or about 9.5% of its GDP.

Market Dynamics

Market Growth Drivers

For the treatment of moderate to severe atopic dermatitis, combination therapies like topical corticosteroids and calcineurin inhibitors have become more popular. Eczema and urticaria had the highest prevalence rates in the adult population, respectively, at 4.4% and 3.4%. These trends are driving the dermatology drugs market in Portugal.

Market Restraints

The dermatology drug must be approved by the National Authority of Medicines and Health Products (INFARMED) before it can be marketed and used in Portugal. Some dermatology drugs may require a prescription from a licensed healthcare provider and may not be available for over-the-counter use. These regulations may prevent new players from entering the dermatological drug market in Portugal.

Competitive Landscape

Key Players

Bial (PRT)
Eurofarma (PRT)
Roche Portugal (PRT)
Sanofi Portugal (PRT)
Pfizer
Novo Nord
GlaxoSmithKline
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The National Authority for Medicines and Health Products (Infarmed) in Portugal is in charge of controlling the regulation of dermatology medications. Portugal's national regulatory body, Infarmed, is in charge of ensuring the security, effectiveness, and caliber of medical products, including medications for treating skin conditions. Infarmed's role in regulating dermatology drugs includes examining requests for marketing authorization, keeping an eye on the security of medications once they are available, and managing the labeling and promotion of medications to guarantee their safe and efficient use. Infarmed also works to maintain the viability of the public health system while making dermatology medications accessible to patients in Portugal at a reasonable cost.

Portugal's National Health Service (Serviço Nacional de Sade, SNS), which is the nation's public healthcare system, pays for dermatology medications. The National Authority for Medicines and Health Products (Infarmed) establishes Portugal's reimbursement guidelines for dermatology medications. The type of medication, the condition it is used to treat, and the unique circumstances of the patient all play a role in how much is reimbursed for dermatology medications. The SNS may fully reimburse some dermatology medications, such as those prescribed to treat skin cancer or other severe skin conditions. Other medications, like those taken for cosmetic reasons, might not be covered by insurance.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.